MFN2 and acute myeloid leukemia: Consistently, time-dependent exposure to doxorubicin, and increased levels of MFN1, MFN2, and OXPHOS in response to doxorubicin, are usually associated with fusion-driven chemoresistance in Jurkat leukemia cells, acute myeloid leukemia (AML), and ovarian cancers [184].